NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Tianjin Institute Of Pharmaceutical Research—Ne »18/09/2009 [Company watch]
Tianyin Pharma Granted GMP for New Solid Dose Facility

Tianyin Pharmaceutical announced it received GMP certification for its new solid dosage manufacturing facility from the SFDA. The company said the new facility will triple its solid dose capacity. Tianyin, which has historically concentrated in TCM, has been branching out into generic versions of western drugs.

 
Tianyin Pharmaceutical announced it received GMP certification for its new solid dosage manufacturing facility from the SFDA. The company said the new facility will triple its solid dose capacity. Tianyin, which has historically concentrated in TCM, has been branching out into generic versions of western drugs. Tianyin Pharma has predicted a 40% increase in revenue for its 2010 fiscal year, which ends June 30, 2010. Eventually the company expects the new facility will provide capacity for $100 million in annual revenues. Although Tianyin will not release its 2009 financial report until next week, the company has said its 2009 revenues were about $42 million and net income totaled $7.5 million. It issued guidance for $59 million in 2010 revenues and $10.5 million in net income. Four of the company products are included in the China Essential Drug List: Azithromycin Dispersible Tablets, Simvastatin Tablets, Hugan Tablets and Xiao Yan Li Dan Capsules and Tablets. Tianyin predicted the EDL may have the effect of doubling these products’ revenue in 2010 to $12 million. Currently, Tianyin’s portfolio includes 39 products, 22 of them listed in the National Medicine Catalog of the National Medical Insurance program. An additional 40 products are in the pipeline.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.